Structure via PubChem · Public domain (PubChem)
pazopanib
Sign in to saveAlso known as PZP034, GW 786034, indazolylpyrimidine 13, GW 78603, GW786034
Pazopanib, sold under the brand name Votrient, is an anti-cancer medication marketed worldwide by Novartis. It is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide.
Key facts
- Drug.S
- 1
- Drug.ATC_suffix
- EX03
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.C
- 21
- Drug.H
- 23
- Drug.N
- 7
- Drug.O
- 2
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 464197511
- Drug.image
- Pazopanib.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 275
- Drug.tradename
- Votrient
via Wikipedia infobox
Chemical data
- Formula
- C21H23N7O2S
- Molecular weight
- 437.5 g/mol
- IUPAC name
- 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide
- SMILES
- CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
- InChIKey
- CUIHSIWYWATEQL-UHFFFAOYSA-N
- XLogP
- 3.1
- Polar surface area
- 127 Ų
- H-bond donors
- 2
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2009
- Admin. routes
- oral
- Indications
- neoplasm, colorectal adenocarcinoma, renal cell carcinoma, sarcoma
via ChEMBL · EBI
Research
2,767 papers- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.Lancet (London, England) · 2012
- Drug review: Pazopanib.Japanese journal of clinical oncology · 2018
- Pazopanib in ovarian cancer.Expert review of anticancer therapy · 2015
- Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.Expert opinion on investigational drugs · 2019
- Pazopanib: a Review in Advanced Renal Cell Carcinoma.Targeted oncology · 2017
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 437.163394
- Has use
- medication
Show 8 more facts
- chemical formula
- C₂₁H₂₃N₇O₂S
- medical condition treated
- renal cell carcinoma
- canonical SMILES
- CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
- subject has role
- protein kinase inhibitors
- World Health Organisation international non-proprietary name
- pazopanib
- stylized name
- PAZOPanib
- Commons category
- Pazopanib
- significant drug interaction
- famotidine
Sources (7)
via Wikidata · CC0
~2 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Contraindications
- Adverse effects
- Overdose
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- References
{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 464197511 | image = Pazopanib.svg | image_class = skin-invert-image | width = 275 | alt =
| pronounce = | tradename = Votrient | Drugs.com = | MedlinePlus = a610013 | DailyMedID = Pazopanib | pregnancy_AU = D | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = | ATC_prefix = L01 | ATC_suffix = EX03 | ATC_supplemental =
Excerpted from Wikipedia’s “pazopanib” article, available under the CC BY-SA 4.0 licence.
Available in 16 languages
- Español
- Français
- Deutsch
- 日本語
- Português
- العربية
- Bahasa Indonesia
- Estonian
- Lithuanian
- Odia
- Polski
- Serbian
- Serbian (Latin)
- Ukrainian
- فارسی
via Wikidata sitelinks · CC0